Back

FDA recommends added trial for ABL Bio’s tovecimig cancer candidate

Verifying
  • FDA recommended an additional tovecimig clinical trial for ABL Bio.
  • ABL Bio’s stock code is 298380, and tovecimig targets biliary tract cancer.
  • The trial must occur before the U.S. partner submits a BLA.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.